Daiichi’s new clot-fighter Savaysa can’t make up for $2.6B Benicar patent loss: analysts

Carly Helfand

Daiichi Sankyo's got a big revenue hurdle coming up, with top treatment set to lose protection next year. A black-box warning on its new drug isn't helping matters. So are wondering what the company can do to plug the forthcoming sales holes.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS